High-throughput screening using the iTLR4 assay could identify new compounds that modulate TLR4 activity, offering therapeutic potential for conditions where TLR4 is implicated, such as sepsis, chronic inflammatory diseases, and certain cancers. Here, TLR4 is linked to cancer.